488 related articles for article (PubMed ID: 29695832)
21. Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
Wen WX; Soo JS; Kwan PY; Hong E; Khang TF; Mariapun S; Lee CS; Hasan SN; Rajadurai P; Yip CH; Mohd Taib NA; Teo SH
Breast Cancer Res; 2016 May; 18(1):56. PubMed ID: 27233495
[TBL] [Abstract][Full Text] [Related]
22. Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.
Nikkilä J; Kumar R; Campbell J; Brandsma I; Pemberton HN; Wallberg F; Nagy K; Scheer I; Vertessy BG; Serebrenik AA; Monni V; Harris RS; Pettitt SJ; Ashworth A; Lord CJ
Br J Cancer; 2017 Jun; 117(1):113-123. PubMed ID: 28535155
[TBL] [Abstract][Full Text] [Related]
23. Integrative genomic analysis reveals functional diversification of APOBEC gene family in breast cancer.
Zhang Y; Delahanty R; Guo X; Zheng W; Long J
Hum Genomics; 2015 Dec; 9():34. PubMed ID: 26682542
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of HPV E6 and APOBEC3B in Upper Urinary Tract Urothelial Carcinoma.
He L; Yang B; Jian D; Luo H; Wang D; Dai N
Dis Markers; 2022; 2022():2147494. PubMed ID: 35903294
[TBL] [Abstract][Full Text] [Related]
25. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
[TBL] [Abstract][Full Text] [Related]
26. Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression.
Chen C; Sui X; Ning H; Sun Y; Du J; Chen X; Zhou X; Chen G; Shen W; Pang L; Zhou X; Shi R; Li W; Wang H; Zhao W; Zhai W; Qi Y; Wu Y; Gao Y
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323433
[TBL] [Abstract][Full Text] [Related]
27. APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy.
Driscoll CB; Schuelke MR; Kottke T; Thompson JM; Wongthida P; Tonne JM; Huff AL; Miller A; Shim KG; Molan A; Wetmore C; Selby P; Samson A; Harrington K; Pandha H; Melcher A; Pulido JS; Harris R; Evgin L; Vile RG
Nat Commun; 2020 Feb; 11(1):790. PubMed ID: 32034147
[TBL] [Abstract][Full Text] [Related]
28. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
Middlebrooks CD; Banday AR; Matsuda K; Udquim KI; Onabajo OO; Paquin A; Figueroa JD; Zhu B; Koutros S; Kubo M; Shuin T; Freedman ND; Kogevinas M; Malats N; Chanock SJ; Garcia-Closas M; Silverman DT; Rothman N; Prokunina-Olsson L
Nat Genet; 2016 Nov; 48(11):1330-1338. PubMed ID: 27643540
[TBL] [Abstract][Full Text] [Related]
29. Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
Kim SH; Ahn S; Suh KJ; Kim YJ; Park SY; Kang E; Kim EK; Kim IA; Chae S; Choi M; Kim JH
Breast Cancer Res Treat; 2020 Oct; 183(3):697-704. PubMed ID: 32715441
[TBL] [Abstract][Full Text] [Related]
30. Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
Brogden KA; Parashar D; Hallier AR; Braun T; Qian F; Rizvi NA; Bossler AD; Milhem MM; Chan TA; Abbasi T; Vali S
BMC Cancer; 2018 Feb; 18(1):225. PubMed ID: 29486723
[TBL] [Abstract][Full Text] [Related]
31. APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism.
Chen TW; Lee CC; Liu H; Wu CS; Pickering CR; Huang PJ; Wang J; Chang IY; Yeh YM; Chen CD; Li HP; Luo JD; Tan BC; Chan TEH; Hsueh C; Chu LJ; Chen YT; Zhang B; Yang CY; Wu CC; Hsu CW; See LC; Tang P; Yu JS; Liao WC; Chiang WF; Rodriguez H; Myers JN; Chang KP; Chang YS
Nat Commun; 2017 Sep; 8(1):465. PubMed ID: 28878238
[TBL] [Abstract][Full Text] [Related]
32. APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression.
Wang D; Li X; Li J; Lu Y; Zhao S; Tang X; Chen X; Li J; Zheng Y; Li S; Sun R; Yan M; Yu D; Cao G; Yang Y
Gut; 2019 Oct; 68(10):1846-1857. PubMed ID: 31154396
[TBL] [Abstract][Full Text] [Related]
33. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
34. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
Wang J; Shaban NM; Land AM; Brown WL; Harris RS
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
[TBL] [Abstract][Full Text] [Related]
35. APOBEC3B expression is promoted by lincNMR collaborating with TGF-β-Smad pathway.
Ota K; Sakai S; Ohhata T; Suzuki T; Uchida C; Niida H; Kitagawa M
Carcinogenesis; 2023 May; 44(1):1-14. PubMed ID: 36335471
[TBL] [Abstract][Full Text] [Related]
36. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
[No Abstract] [Full Text] [Related]
37. Replication catastrophe induced by cyclic hypoxia leads to increased APOBEC3B activity.
Bader SB; Ma TS; Simpson CJ; Liang J; Maezono SEB; Olcina MM; Buffa FM; Hammond EM
Nucleic Acids Res; 2021 Jul; 49(13):7492-7506. PubMed ID: 34197599
[TBL] [Abstract][Full Text] [Related]
38. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.
Yamazaki H; Shirakawa K; Matsumoto T; Hirabayashi S; Murakawa Y; Kobayashi M; Sarca AD; Kazuma Y; Matsui H; Maruyama W; Fukuda H; Shirakawa R; Shindo K; Ri M; Iida S; Takaori-Kondo A
Sci Rep; 2019 May; 9(1):7122. PubMed ID: 31073151
[TBL] [Abstract][Full Text] [Related]
39. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
Shi MJ; Meng XY; Lamy P; Banday AR; Yang J; Moreno-Vega A; Chen CL; Dyrskjøt L; Bernard-Pierrot I; Prokunina-Olsson L; Radvanyi F
Eur Urol; 2019 Jul; 76(1):9-13. PubMed ID: 30975452
[TBL] [Abstract][Full Text] [Related]
40. Genomic Characterization Revealed PM
Fan R; Xu L; Cui B; Li D; Sun X; Qi Y; Rao J; Wang K; Wang C; Zhao K; Zhao Y; Dai J; Chen W; Shen H; Liu Y; Yu D
Environ Sci Technol; 2023 May; 57(17):6854-6864. PubMed ID: 37071573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
